ALK and adenocarcinoma: Survival analysis demonstrated that younger age, female sex, adenocarcinoma histology, p-stage II, low CD score, positive EGFR/ALK mutation, and ICI were associated with better OS in those who treated with adjuvant chemotherapy by univariate analysis.